Ross River virus vaccine - Ology Bioservices

Latest Information Update: 06 Oct 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Baxter Healthcare Corporation
Developer Nanotherapeutics
Class Viral vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Ross River virus infections

Most Recent Events

02 Oct 2017 Nanothearpeutics is now called Ology Bioservices
23 Apr 2013 Baxter completes a phase III follow-up trial for Ross River virus infections in Australia (NCT01604746)
31 Oct 2012 Baxter completes a phase III trial in Ross River virus infections in Australia (NCT01242670)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.